Bristol Myers Squibb Moves Closer to New Multiple Myeloma Treatment

FDA accepted Bristol Myers Squibb’s new drug application for mezigdomide (oral) in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma. The acceptance is a positive regulatory milestone for the investigational therapy and may support expectations around potential future approval and uptake, though no efficacy or timeline outcomes were provided in the report.

Analysis

FDA accepted Bristol Myers Squibb’s new drug application for mezigdomide (oral) in combination with carfilzomib and dexamethasone for relapsed/refractory multiple myeloma. The acceptance is a positive regulatory milestone for the investigational therapy and may support expectations around potential future approval and uptake, though no efficacy or timeline outcomes were provided in the report.